<DOC>
	<DOCNO>NCT00858754</DOCNO>
	<brief_summary>This purpose study evaluate safety effectiveness subcutaneous ( injection beneath skin ) form methylnaltrexone subject cancer-related pain constipation take opioids . The length participation 7 week .</brief_summary>
	<brief_title>Study Evaluating Safety &amp; Efficacy Subcutaneous Methylnaltrexone Opioid-Induced Constipation Cancer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Is man woman age 18 year old . Has body weight &gt; = 38 kg . Has cancer ( active remission ) , cancerrelated pain ( ie , pain due cancer treatment cancer ) . Has life expectancy &gt; = 6 month . Has performance status 0 , 1 , 2 base Eastern Cooperative Oncology Group ( ECOG ) scale . Is take opioids cancerrelated pain , asneeded dos . Has diagnosis OIC determine investigator . Is willing follow protocol instruction laxative use study . Has history chronic constipation start opioids . Has renal disease receive dialysis . Has ostomy stool . Is pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>opioid induce constipation</keyword>
	<keyword>Cancer patient</keyword>
	<keyword>methylnaltrexone</keyword>
</DOC>